Publication: CD63 is a diagnostic marker of prostate cancer and a prognostic marker of biochemical progression following radical prostatectomy
Authors
Marit Bernhardt1 ; Isabella Federica Bollen ; Tobias Kreft ; Anna Katrin Scherping ; Xiaolin Zhou ; Manuel Ritter ; Jörg Ellinger ; Carsten Stephan ; Glen Kristiansen ; Elisabeth Dingendorf
item.page.secondaryauthor
item.page.director
Publisher
publication.page.editor
publication.page.department
DOI
https://doi.org/10.14670/HH-18-981
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Aims. We aimed to analyze CD63, a cell
surface protein that has been associated with tumor
aggressiveness in several cancers, including breast,
colorectal, and lung cancer, as well as melanoma, in
prostate cancer.
Methods. CD63 expression was analyzed immuno
histochemically in a cohort of primary prostate cancers
from 281 patients. The results were correlated with
clinico-pathologic parameters, including biochemical
recurrence. In addition, CD63 expression in 251 of the
281 patients with prostate cancer was compared with
CD63 expression in matched benign tissue samples (490
tissue samples). The analysis was performed
automatically using the open-source software QuPath©
and tested for statistical significance. For comparison
with the diagnostic markers AMACR and GOLPH2,
CD63 was analyzed in an additional cohort of 198
prostate cancers.
Results. CD63 expression was found in 100% of
prostate cancer cases and benign tissue spots. Increased
CD63 expression was significantly associated with
higher tumor stage (pT), tumor grade (ISUP), as well as
shorter progression-free survival (PFS). Compared with
the CD63 intensity of benign tissue, expression in tumor
tissue was higher in >80% of cases. In addition,
combining the expression of CD63 and AMACR,
positivity reached 97.2%, making CD63 a promising
diagnostic biomarker in challenging cases.
Conclusions. CD63 is commonly overexpressed in
prostate cancer, and higher levels are associated with
earlier biochemical tumor progression; hence, CD63 is a promising diagnostic and prognostic biomarker in
primary prostate cancer.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/